1. Home
  2. GGAL vs CYTK Comparison

GGAL vs CYTK Comparison

Compare GGAL & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Financiero Galicia S.A.

GGAL

Grupo Financiero Galicia S.A.

N/A

Current Price

$43.16

Market Cap

7.4B

Sector

Finance

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$59.89

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGAL
CYTK
Founded
1905
1997
Country
Argentina
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
7.6B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
GGAL
CYTK
Price
$43.16
$59.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
18
Target Price
$69.00
$87.56
AVG Volume (30 Days)
1.2M
1.7M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
3.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$8.56
$9.79
Revenue Next Year
$17.81
$302.66
P/E Ratio
$13.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.89
$29.31
52 Week High
$66.24
$70.98

Technical Indicators

Market Signals
Indicator
GGAL
CYTK
Relative Strength Index (RSI) 39.70 40.30
Support Level $25.97 $59.25
Resistance Level $54.05 $65.93
Average True Range (ATR) 2.00 2.65
MACD 0.03 -0.32
Stochastic Oscillator 24.75 3.98

Price Performance

Historical Comparison
GGAL
CYTK

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: